Global Isocitrate Dehydrogenase Inhibitors Market - 2023-2030

Global Isocitrate Dehydrogenase Inhibitors Market - 2023-2030

Global Isocitrate Dehydrogenase Inhibitors Market reached US$ XX billion in 2022 and is expected to reach US$ XX million by 2030 growing at a CAGR of XX% during the forecast period 2023-2030.

Isocitrate Dehydrogenase Inhibitors alter the activity of IDH enzymes resulting in a reduction of α-ketoglutarate to D-2-hydroxyglutarate. Isocitrate dehydrogenase 1 (IDH1) inhibitors are drugs used for treating different types of cancers. IDH1 is a gene that makes an enzyme isocitrate dehydrogenase.

These inhibitors target mutated IDH enzymes hindering their abnormal activity and impeding cancer cell proliferation. The therapeutic aim is to induce differentiation and apoptosis in cancer cells by providing a targeted approach in oncology.

Market Dynamics

Increasing prevalence of acute myeloid leukemia

The increasing prevalence of acute myeloid leukemia acts as a significant driver for market growth. Acute myeloid leukemia progresses rapidly with myeloid cells interfering with the production of normal white blood cells, red blood cells, and platelets.

For instance, according to the American Society of Clinical Oncology, acute myeloid leukemia makes up 31% of all adult leukemia cases. It is estimated that 11,310 deaths from this disease occur in the United States in 2023.

Additionally, according to the Indian Council of Medical Research, its annual incidence is 2-3 per 100,000. The incidence increases with age and it is less than 1 per 100,000 under 30 years of age and 17 per 100,000 by 75 years.

Furthermore, significant growth drivers such as the rising clinical trials for isocitrate dehydrogenase inhibitors, and new drug approvals are expected to drive the market in the forecast period.

Side effects associated with isocitrate dehydrogenase inhibitors

The side effects of IDH inhibitors can hamper the market growth. Common side effects of isocitrate dehydrogenase inhibitors include fatigue, decreased hemoglobin level, decreased white blood cell count, increased cholesterol, nausea, and decreased electrolytes.

Segment Analysis

The global isocitrate dehydrogenase inhibitors market is segmented based on type, application, route of administration, and region.

The IDH1 Inhibitor segment accounted for approximately 41.9% of the market share

The IDH1 Inhibitor segment is expected to hold the largest market share over the period forecast due to the increasing number of clinical trials. A total number of 33 clinical trials were conducted for IDH 1 inhibitors.

For instance, according to clinicaltrial.gov, on March 1, 2021, M.D. Anderson Cancer Center started a clinical trial on the study of oral Decitabine/Cedazuridine and Venetoclax in combination with the targeted mutant idh1 inhibitor ivosidenib. It is currently in phase 2 trial and the expected study completion date is November 2024

Additionally, on January 4, 2023, Groupe Francophone des Myelodysplasies started a clinical trial on Phase II multicenter study of IDH1 inhibitor in patients with IDH1 mutated Myelodysplastic Syndrome. The expected study completion date is April 2023. Hence, due to the above factors, the segment is expected to hold the largest market share.

Geographical Analysis

North America is expected to hold a significant position in the global isocitrate dehydrogenase inhibitors market share

The global isocitrate dehydrogenase inhibitors market is segmented into North America, Europe, Asia Pacific, South America, Middle East, and Africa.

North America has maintained a significant market proportion due to factors such as the rising prevalence of cholangiocarcinoma, drug approval, and increasing healthcare expenditure, this trend is anticipated to continue throughout the forecast period.

For instance, in December 2022, the FDA approved Rezlidhia (olutasidenib) capsules for adult patients with relapsed or refractory acute myeloid leukemia with a susceptible IDH1 mutation.

Additionally, an estimated 8,000 people in the United States are diagnosed with cholangiocarcinoma each year, and up to 20% of patients with cholangiocarcinoma harbor IDH1 mutations. Thus, the above factors help to drive the region’s growth.

COVID-19 Impact Analysis

The COVID-19 pandemic has had a significant impact on the global isocitrate dehydrogenase inhibitors market. The onset of the pandemic in early 2020 led to widespread lockdowns and restrictions, impacting regular diagnoses, treatment, product launches, and consultations worldwide. With the outbreak of the pandemic, many pharmaceutical or medical device manufacturing units faced labor shortages and were unable to travel to work due to lockdown restrictions. Therefore, owing to the above factors, the isocitrate dehydrogenase inhibitors market is expected to be moderately affected over the forecast period.

Market Segmentation

By Type
• IDH1 Inhibitor
• IDH2 Inhibitor
• Others

By Application
• Acute myeloid leukemia
• Cholangiocarcinoma
• Others

By Route of Administration
• Oral
• Parenteral

By Region
• North America
U.S.
Canada
Mexico
• Europe
Germany
U.K.
France
Spain
Italy
Rest of Europe
• South America
Brazil
Argentina
Rest of South America
• Asia-Pacific
China
India
Japan
Australia
Rest of Asia-Pacific
• Middle East and Africa

Competitive Landscape

The major global players in the market include Merck KGaA, Adooq Bioscience LLC, Agios Pharmaceuticals Inc., Rigel Pharmaceuticals Inc., Servier, Celgene Corporation, Bristol Myers Squibb, Philogen SpA among others.

Key Developments
• In May 2023, Servier Pharmaceuticals received European Commission approval for Tibsovo in IDH1-mutated Acute Myeloid Leukemia and IDH1-mutated Cholangiocarcinoma.

Why Purchase the Report?
• To visualize the global isocitrate dehydrogenase inhibitors market segmentation based on type, application, route of administration and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of global isocitrate dehydrogenase inhibitors market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global isocitrate dehydrogenase inhibitors market report would provide approximately 61 tables, 69 figures, and 185 Pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies